Blog

Project To Increase RNAP Manufacturing Capacity and Reduce Unit Costs of Goods Project Slated For Completion Coincident with Company’s Planned Initiation of GMP Manufacturing for Linea™ DNA IVT Templates STONY BROOK, N.Y., and JUPITER, F.L. March 18, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in PCR-based DNA […]

STONY BROOK, N.Y., March 14, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, will showcase its Linea™ IVT and Linea™ DNA platforms at the 24th Annual World Vaccine Congress, which will be held April 1 – 4, 2024. Applied DNA sales team members will be available during the Congress […]

Agreement Seeks to Leverage Linea IVT Platform to Enable Kudo Bio to Offer a Differentiated mRNA Manufacturing Capability with Mitigated dsRNA and Reduced Turnaround Times STONY BROOK, N.Y., and NEEDHAM, M.A. – December 14, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, and Kudo Biotechnology (Kudo Bio), […]

STONY BROOK, N.Y. November 28, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced the receipt of a follow-on order for Linea™ DNA valued above the mid-six figures. The order was placed under a long-standing supply agreement for the bulk manufacture of Linea […]

– Extension Increases Total Addressable Market to Include Both Conventional Non-Amplifying mRNA and saRNA – – Extension Enabled by the Company’s Ongoing Platform Development and Optimization – STONY BROOK, N.Y. November 16, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, announced the expansion of its […]

Preclinical Orders for Additional Customers Underway STONY BROOK, N.Y. November 9, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced that it has successfully manufactured and shipped its first research use only quantity of self-amplifying mRNA (saRNA) template generated by its Linea™ DNA […]

Agreement Focuses on the Accelerated Development of LNP-encapsulated LineaDNA™ Vaccines to Eliminate the Use of Plasmid DNA and Reduce the Dependence on Extreme Cold Chains of Today’s mRNA Vaccines STONY BROOK, NY and ITHACA, NY / ACCESSWIRE / September 14, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (‘Applied DNA’ or the “Company”), a leader in polymerase chain […]

– Experienced Biopharma/Pharmaceutical Executive to Lead Implementation of cGMP-quality LineaDNA™ Capability for IVT mRNA Production – – Previously Led Manufacturing Operations Scale-up for the BioNTech/Pfizer mRNA COVID-19 Vaccine at CDMO Division of Maravai LifeSciences – STONY BROOK, N.Y. – September 6, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, […]

STONY BROOK, N.Y. – July 18, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in PCR-based DNA technologies, today announced the participation of LineaRx, Inc., its majority-owned biotherapeutics subsidiary, in upcoming mRNA industry conferences in Boston: “We are eager to introduce our newly launched Linea™ IVT platform and engage therapy developers […]